FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

Guide on Selective Drug Safety Data Collection

FDA posts a final guidance entitled E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical T...

latest-news-card-1
Human Drugs

FDA Accepts Protalix, Chiesi Fabry Disease BLA Resubmission

FDA accepts for review a Protalix BioTherapeutics and Chiesi BLA resubmission for PRX102 (pegunigalsidase alfa) for treating adult patients with Fabry...

latest-news-card-1
Federal Register

Draft Guide on ANDA Pre-inspection Correspondence

Federal Register notice: FDA makes available a revised draft guidance entitled ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Ge...

latest-news-card-1
Human Drugs

ANDA Pre-Submission Facility Correspondence Guidance

FDA posts a draft guidance entitled ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions.

Medical Devices

Getinge Intra-Aortic Balloon Pumps on Shortage Lis

FDA adds Getinge Maquet/Datascope Intra-Aortic Balloon Pump devices to its device shortage list.

latest-news-card-1
Human Drugs

Draft Guide on Bioequivalence Statistical Approaches

FDA releases a draft guidance entitled Statistical Approaches to Establishing Bioequivalence that is intended to provide recommendations for submittin...

latest-news-card-1
Federal Register

Oncologic Drugs Committee Renewed for 2 Years

Federal Register notice: FDA announces the renewal of its Oncologic Drugs Advisory Committee for an additional two years beyond the charter expiration...

latest-news-card-1
Human Drugs

NECC Co-owner Sentenced to 1 Year Jail Term

A Boston federal judge sentences former co-owner of now-closed New England Compounding Center, Gregory Conigliaro, to one year in prison for his role ...

latest-news-card-1
FDA General

Biden Signs Medical Marijuana/Cannabidiol Research Law

President Biden signs into law HR 8454, the Medical Marijuana and Cannabidiol Research Expansion Act.

latest-news-card-1
Biologics

FDA Rejects Y-mAbs BLA for Brain Condition

FDA sends Y-mAbs Therapeutics a complete response letter on its BLA for I-omburtamab and its use in treating CNS/leptomeningeal metastasis from neurob...